Nephrocalcinosis
Disease Details
Family Health Simplified
- Description
- Nephrocalcinosis is a medical condition characterized by the accumulation of calcium deposits in the renal parenchyma, leading to potential kidney dysfunction.
- Type
-
Nephrocalcinosis itself is not typically classified directly under a single type of genetic transmission. However, some underlying conditions that can lead to nephrocalcinosis may have a genetic basis. For instance:
1. **Primary hyperoxaluria**: This is inherited in an autosomal recessive manner.
2. **Bartter syndrome**: Also generally inherited in an autosomal recessive manner.
3. **Dent disease**: Inherited in an X-linked recessive pattern.
These genetic conditions can increase the risk of developing nephrocalcinosis. - Signs And Symptoms
-
Though this condition is usually asymptomatic, if symptoms are present they are usually related to the causative process, (e.g. hypercalcemia). Some of the symptoms that can happen are blood in the urine, fever and chills, nausea and vomiting, severe pain in the belly area, flanks of the back, groin, or testicles.
These include renal colic, polyuria and polydipsia:
Renal colic is usually caused by pre-existing nephrolithiasis, as may occur in patients with chronic hypercalciuria. Less commonly, it can result from calcified bodies moving into the calyceal system.
Nocturia, polyuria, and polydipsia from reduced urinary concentrating capacity (i.e. nephrogenic diabetes insipidus) as can be seen in hypercalcemia, medullary nephrocalcinosis of any cause, or in children with Bartter syndrome in whom essential tubular salt reabsorption is compromised.There are several causes of nephrocalcinosis that are typically acute and present only with kidney failure. These include tumor lysis syndrome, acute phosphate nephropathy, and occasional cases of enteric hyperoxaluria. - Prognosis
- The prognosis of nephrocalcinosis is determined by the underlying cause. Most cases of nephrocalcinosis do not progress to end stage renal disease, however if not treated it can lead to renal dysfunction this includes primary hyperoxaluria, hypomagnesemic hypercalciuric nephrocalcinosis and Dent's disease. Once nephrocalcinosis is found, it is unlikely to be reversed, however, partial reversal has been reported in patients who have had successful treatment of hypercalciuria and hyperoxaluria following corrective intestinal surgery.
- Onset
- The onset of nephrocalcinosis can vary depending on the underlying cause. It may be congenital, developing in infancy if associated with genetic or metabolic disorders. In other cases, it can develop over time due to chronic conditions such as hyperparathyroidism, renal tubular acidosis, or prolonged use of certain medications. It typically becomes symptomatic as the calcium deposits accumulate and cause kidney dysfunction.
- Prevalence
- The prevalence of nephrocalcinosis varies depending on the underlying cause and population studied. It is not a common condition but is frequently associated with specific medical conditions such as primary hyperparathyroidism, renal tubular acidosis, and medullary sponge kidney. Precise prevalence rates are not well-documented, but it remains a relatively rare condition in the general population.
- Epidemiology
-
Nephrocalcinosis refers to the deposition of calcium salts in the renal parenchyma.
### Epidemiology:
- **Prevalence**: Nephrocalcinosis is relatively uncommon and its prevalence varies depending on the population studied and existing risk factors. It is often higher in patients with underlying metabolic disorders.
- **Age**: It can occur at any age but is more frequently identified in adults. Pediatric cases are often associated with specific congenital or metabolic conditions.
- **Gender**: There is no strong gender predilection, though some studies suggest a slight male predominance.
- **Risk Factors**: Common risk factors include hypercalcemia, hypercalciuria, renal tubular acidosis, primary hyperparathyroidism, chronic kidney disease, and certain genetic conditions like Bartter syndrome or idiopathic hypercalciuria.
For more precise epidemiological data, regional studies and population-specific research would provide clearer insights. - Intractability
- Nephrocalcinosis itself is not typically described as intractable, but it can be challenging to manage depending on the underlying cause and extent of kidney damage. Treatment focuses on addressing the root cause of calcium deposition and preventing further progression. Early intervention and ongoing management can improve outcomes, but some cases may be more resistant to treatment.
- Disease Severity
- Nephrocalcinosis can vary in severity depending on the extent of calcium deposition in the kidneys. Mild cases may be asymptomatic, whereas severe cases can lead to significant kidney damage, impaired kidney function, and complications such as kidney stones, chronic kidney disease, or renal failure.
- Healthcare Professionals
- Disease Ontology ID - DOID:12679
- Pathophysiology
-
Nephrocalcinosis is characterized by the deposition of calcium salts in the renal parenchyma. Its pathophysiology involves several mechanisms:
1. **Hypercalcemia**: Elevated levels of calcium in the blood can lead to excess calcium being filtered by the kidneys, subsequently precipitating in the renal tubules.
2. **Hyperphosphatemia**: Excess phosphate can combine with calcium to form insoluble calcium phosphate, leading to deposition in the kidneys.
3. **Hypercalciuria**: Increased urinary excretion of calcium can promote the formation of calcium crystals within the renal tubules.
4. **Tubular Injury**: Damage to the renal tubules, caused by toxins or underlying genetic conditions, can enhance calcium deposition.
5. **Metabolic Acidosis**: Conditions that cause systemic or renal tubular acidosis can increase the release of calcium from bone and its deposition in the kidneys.
Nephrocalcinosis is often associated with underlying metabolic or genetic disorders, renal tubular acidosis, hyperparathyroidism, vitamin D intoxication, and certain medications. - Carrier Status
- Nephrocalcinosis is typically not associated with a "carrier status" as it is not a single-gene inherited condition like some types of cystic fibrosis or sickle cell disease. Instead, nephrocalcinosis refers to the deposition of calcium salts in the renal tissue, often related to underlying metabolic disorders, renal tubular acidosis, hyperparathyroidism, or hypercalcemia. It is a condition that can result from various genetic and non-genetic factors rather than being carried as a genetic trait.
- Mechanism
- Nephrocalcinosis is caused by an increase in the urinary excretion of calcium, phosphate, and/or oxalate. Nephrocalcinosis is closely associated with nephrolithiasis, and patients frequently present with both conditions, however there have been cases where one occurs without the other. Calcium oxalate and calcium phosphate crystals form when the concentration of the reactants exceeds the limit of solubility of these compounds under the physiological conditions prevailing locally in the organism. The deposits are collected in the inner medullary interstitium in the basement membranes of the thin limbs of the loop of Henle. The calcium phosphate plaques can enlarge into the surrounding interstitial tissue, or even rupture into the tubule lumen and can promote calcium oxalate stone formation.
- Treatment
- Increasing fluid intake to yield a urine output of greater than 2 liters a day can be advantageous for all patients with nephrocalcinosis. Patients with hypercalciuria can reduce calcium excretion by restricting animal protein, limiting sodium intake to less than 100 meq a day and being lax of potassium intake. If changing one's diet alone does not result in a suitable reduction of hypercalciuria, a thiazide diuretic can be administered in patients who do not have hypercalcemia. Citrate can increase the solubility of calcium in urine and limit the development of nephrocalcinosis. Citrate is not given to patients who have urine pH equal to or greater than 7.
- Compassionate Use Treatment
-
For nephrocalcinosis, compassionate use treatments and off-label or experimental treatments are generally considered on a case-by-case basis, often focusing on the underlying cause of the condition. Some potential approaches include:
1. **Thiazide Diuretics**: These are sometimes used off-label to reduce calcium excretion in the urine, though their effectiveness can vary depending on individual patient factors.
2. **Bisphosphonates**: Occasionally considered off-label to manage hypercalcemia, although their role in nephrocalcinosis specifically is not well established.
3. **Loop Diuretics**: Use of loop diuretics like furosemide can help to manage hypercalcemia, which may be associated with nephrocalcinosis.
4. **Steroids**: In certain conditions like sarcoidosis that can lead to nephrocalcinosis, corticosteroids might be used to reduce inflammation and calcium levels.
5. **Citrate Therapy**: Potassium or sodium citrate may be prescribed off-label to bind calcium and reduce stone formation.
Always consult healthcare providers for decisions regarding treatments, as they need to be tailored to individual patient conditions and underlying causes. - Lifestyle Recommendations
-
For nephrocalcinosis, lifestyle recommendations generally focus on preventing further kidney damage and managing underlying conditions. Recommendations may include:
1. **Hydration**: Maintain adequate fluid intake to help prevent the formation of kidney stones and facilitate the flushing of calcium deposits.
2. **Diet**: Follow a balanced diet that controls calcium and oxalate intake, as advised by your healthcare provider. This may involve reducing high-oxalate foods like spinach, nuts, and chocolate.
3. **Limit salt**: Reduce sodium intake to help manage blood pressure and reduce the risk of stone formation.
4. **Medication Adherence**: Take prescribed medications to manage conditions like hyperparathyroidism or other metabolic disorders that can contribute to nephrocalcinosis.
5. **Regular Monitoring**: Undergo regular check-ups with your healthcare provider to monitor kidney function and calcium levels.
6. **Exercise**: Engage in regular physical activity to improve overall health and maintain a healthy weight.
Always consult with a healthcare professional for personalized advice and treatment. - Medication
-
Nephrocalcinosis involves the deposition of calcium salts in the renal parenchyma. Treatment generally focuses on addressing the underlying cause and preventing further calcium deposition. Medications that may be used include:
1. Thiazide diuretics: These can decrease urine calcium levels, helping to reduce calcium buildup.
2. Sodium bicarbonate or potassium citrate: These alkalinize the urine, which can help prevent calcium stones.
3. Phosphate binders: These reduce calcium-phosphate product in cases of hyperphosphatemia.
Specific treatment should be tailored based on the underlying condition, such as hyperparathyroidism, renal tubular acidosis, or sarcoidosis. Consult a healthcare provider for an accurate diagnosis and treatment plan. - Repurposable Drugs
-
There is currently limited specific information on repurposable drugs for nephrocalcinosis, a condition characterized by calcium deposition in the kidneys. However, treatment generally focuses on addressing the underlying cause, such as managing hypercalcemia or hypercalciuria. Potential repurposable drugs may include:
- **Thiazide diuretics**: These are often used to reduce urinary calcium excretion.
- **Corticosteroids**: Can be used if nephrocalcinosis is due to certain inflammatory conditions.
Consultation with a healthcare provider is essential for personalized treatment options. - Metabolites
- Nephrocalcinosis is characterized by the deposition of calcium salts in the renal parenchyma. Metabolites associated with this condition include calcium, phosphate, and oxalate. Elevated levels of these substances can contribute to the formation of calcium phosphate or calcium oxalate crystals in the kidneys.
- Nutraceuticals
-
Nutraceuticals, such as certain dietary supplements and functional foods, may help manage nephrocalcinosis, although they should be used cautiously and under medical supervision. Potential options include:
1. **Magnesium Supplements**: May reduce calcium oxalate stone formation.
2. **Citrate-Supplemented Products**: Potassium citrate or lemon juice can alkalinize urine and reduce stone formation.
3. **Vitamin B6 (Pyridoxine)**: Can help reduce oxalate levels in the urine.
Always consult a healthcare provider before starting any nutraceuticals for nephrocalcinosis. Nutraceutical efficacy can vary, and some might interfere with other treatments or conditions. - Peptides
- Nephrocalcinosis is a condition where calcium deposits form in the kidneys. It's not directly caused by peptides. Management typically involves addressing the underlying cause, such as controlling levels of calcium, phosphate, and vitamin D. Advanced treatments, like nanotechnology-based therapies, are still in experimental stages and not standard practice yet.